Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Advances in Molecular Research and Novel Diagnostic Technics of Hematological...
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Molecular Research and Novel Diagnostic Technics of Hematological Malignancies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 6572

Special Issue Editor

Prof. Dr. Maria Moschovi

E-Mail Website
Guest Editor
Hematology/Oncology Unit, 1st Department of Pediatrics, "Agia Sophia" Children's Hospital, School of Medicine, National and Kapodistrian University of Athens, 10679 Athens, Greece
Interests: hematology; molecular biology; precision medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

The Special Issue follows the publication of the first edition of "Hematological Malignancies”, which presented eight high-quality papers. The new Issue of International Journal of Molecular Sciences, “Advances in Molecular Research and Novel Diagnostic Technics of Hematological Malignancies”, is offering views of the progress of molecular science on two fronts under the overarching scope of hematological malignancies for children and adults.

Precision medicine implies discovery, as well as accurate and deep diagnostics of pathogenic molecular pathways. As a matter of fact, targeted therapies aim to restore disturbed pathways rather than individual lesions. In this perspective, articles on molecular research, which foster the development of new therapeutics in hematological malignancies, would be highly attractive and welcomed for this Special Issue.

In parallel, new diagnostic technics based on the molecular alterations of malignancies enhance the nosological classification and estimation of disease extent. Artificial intelligence and machine learning integrate multi-source diagnostic information. Of great interest in the field of hematological malignancies, imaging methods of positron emission tomography scanning with newer radioisotopes, diffusion-weighted magnetic resonance imaging (MRI), non-invasive liquid biopsies, single-cell RNA and whole-transcriptome sequencing are examples of subjects to be included in the Special Issue.

We are looking forward to receiving high-quality original research articles and reviews paving the road to improved understanding and treatment of these diseases.

Authors are encouraged to elaborate on their subject of predilection and expertise to conceptualize the potential of these advances in hematological malignancies. We are looking forward to exploring this new era in hematology.

Prof. Dr. Maria Moschovi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular biology in leukemia
  • molecular biology in leukemia
  • molecular pathways
  • single-cell sequencing
  • whole-genome sequencing
  • whole-transcriptome sequencing
  • multi-omics
  • artificial intelligence
  • imaging

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

12 pages, 2942 KiB  
Article
Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
by Myra Langendonk, Nienke A. M. Smit, Wouter Plattel, Arjan Diepstra, Tom van Meerten and Lydia Visser
Int. J. Mol. Sci. 2022, 23(22), 13751; https://doi.org/10.3390/ijms232213751 - 9 Nov 2022
Cited by 2 | Viewed by 1303
Abstract
The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the current era there are new opportunities for less toxic and more targeted treatment options. In this respect, the anti-apoptotic [...] Read more.
The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the current era there are new opportunities for less toxic and more targeted treatment options. In this respect, the anti-apoptotic pathway is an attractive target since Hodgkin tumor cells abundantly express components of this pathway. We measured the effect of BH3 mimetics that interfere with anti-apoptotic proteins in cell lines, also in combination with the standard of care chemotherapeutic doxorubicin and the recently discovered preclinically active tamoxifen. Several anti-apoptotic BCL-2 family proteins were expressed in each case (n = 84) and in HL cell lines (n = 5). Cell lines were checked for sensitivity to BH3 mimetics by BH3 profiling and metabolic assays and monotherapy was only partially successful. Doxorubicin was synergistic with a BCL-XL inhibitor and BCL2/XL/W inhibitor navitoclax. Tamoxifen that targets the estrogen receptor β present in the mitochondria of the cell lines, could induce cell death, and was synergistic with several BH3 mimetics including/as well as navitoclax. In conclusion, targeting the anti-apoptotic pathway by the triple inhibitor navitoclax in combination with doxorubicin or tamoxifen is a promising treatment strategy in HL. Full article
(This article belongs to the Special Issue Advances in Molecular Research and Novel Diagnostic Technics of Hematological Malignancies)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

20 pages, 2302 KiB  
Review
Contingent Synergistic Interactions between Non-Coding RNAs and DNA-Modifying Enzymes in Myelodysplastic Syndromes
by Argiris Symeonidis, Theodora Chatzilygeroudi, Vasiliki Chondrou and Argyro Sgourou
Int. J. Mol. Sci. 2022, 23(24), 16069; https://doi.org/10.3390/ijms232416069 - 16 Dec 2022
Cited by 3 | Viewed by 2059
Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders with maturation and differentiation defects exhibiting morphological dysplasia in one or more hematopoietic cell lineages. They are associated with peripheral blood cytopenias and by increased risk for progression into acute [...] Read more.
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders with maturation and differentiation defects exhibiting morphological dysplasia in one or more hematopoietic cell lineages. They are associated with peripheral blood cytopenias and by increased risk for progression into acute myelogenous leukemia. Among their multifactorial pathogenesis, age-related epigenetic instability and the error-rate DNA methylation maintenance have been recognized as critical factors for both the initial steps of their pathogenesis and for disease progression. Although lower-risk MDS is associated with an inflammatory bone marrow microenvironment, higher-risk disease is delineated by immunosuppression and clonal expansion. “Epigenetics” is a multidimensional level of gene regulation that determines the specific gene networks expressed in tissues under physiological conditions and guides appropriate chromatin rearrangements upon influence of environmental stimulation. Regulation of this level consists of biochemical modifications in amino acid residues of the histone proteins’ N-terminal tails and their concomitant effects on chromatin structure, DNA methylation patterns in CpG dinucleotides and the tissue-specific non-coding RNAs repertoire, which are directed against various gene targets. The role of epigenetic modifications is widely recognized as pivotal both in gene expression control and differential molecular response to drug therapies in humans. Insights to the potential of synergistic cooperations of epigenetic mechanisms provide new avenues for treatment development to comfort human diseases with a known epigenetic shift, such as MDS. Hypomethylating agents (HMAs), such as epigenetic modulating drugs, have been widely used in the past years as first line treatment for elderly higher-risk MDS patients; however, just half of them respond to therapy and are benefited. Rational outcome predictors following epigenetic therapy in MDS and biomarkers associated with disease relapse are of high importance to improve our efforts in developing patient-tailored clinical approaches. Full article
(This article belongs to the Special Issue Advances in Molecular Research and Novel Diagnostic Technics of Hematological Malignancies)
►▼ Show Figures

Figure 1

0 pages, 2535 KiB  
Review
RETRACTED: Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies
by Mariam Markouli, Dimitrios Strepkos and Christina Piperi
Int. J. Mol. Sci. 2022, 23(21), 13657; https://doi.org/10.3390/ijms232113657 - 7 Nov 2022
Cited by 3 | Viewed by 2325 | Retraction
Abstract
Hematologic malignancies are a large and heterogeneous group of neoplasms characterized by complex pathogenetic mechanisms. The abnormal regulation of epigenetic mechanisms and specifically, histone modifications, has been demonstrated to play a central role in hematological cancer pathogenesis and progression. A variety of epigenetic [...] Read more.
Hematologic malignancies are a large and heterogeneous group of neoplasms characterized by complex pathogenetic mechanisms. The abnormal regulation of epigenetic mechanisms and specifically, histone modifications, has been demonstrated to play a central role in hematological cancer pathogenesis and progression. A variety of epigenetic enzymes that affect the state of histones have been detected as deregulated, being either over- or underexpressed, which induces changes in chromatin compaction and, subsequently, affects gene expression. Recent advances in the field of epigenetics have revealed novel therapeutic targets, with many epigenetic drugs being investigated in clinical trials. The present review focuses on the biological impact of histone modifications in the pathogenesis of hematologic malignancies, describing a wide range of therapeutic agents that have been discovered to target these alterations and are currently under investigation in clinical trials. Full article
(This article belongs to the Special Issue Advances in Molecular Research and Novel Diagnostic Technics of Hematological Malignancies)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research, Review

1 pages, 155 KiB  
Retraction
RETRACTED: Markouli et al. Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies. Int. J. Mol. Sci. 2022, 23, 13657
by Mariam Markouli, Dimitrios Strepkos and Christina Piperi
Int. J. Mol. Sci. 2024, 25(7), 3762; https://doi.org/10.3390/ijms25073762 - 28 Mar 2024
Viewed by 437
Abstract
The International Journal of Molecular Sciences Editorial Office retracts the article “Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies” [...] Full article
(This article belongs to the Special Issue Advances in Molecular Research and Novel Diagnostic Technics of Hematological Malignancies)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop